Valuation: Immunovia AB

Market Cap 124M 12.76M 11.19M 10.34M 9.51M 17.94M 1.23B 18.23M 48.47M 602M 47.92M 46.88M 2.07B P/E 2026 *
-1.84x
P/E 2027 * -4.6x
Enterprise Value 56.64M 5.85M 5.12M 4.74M 4.36M 8.22M 564M 8.35M 22.2M 276M 21.95M 21.47M 950M EV / Sales 2026 *
17.7x
EV / Sales 2027 * 2.87x
Free-Float
89.3%
Yield 2026 *
-
Yield 2027 * -
1 day-0.54%
1 week-6.98%
Current month-5.74%
1 month-4.17%
3 months-21.79%
6 months-5.65%
Current year-19.03%
1 week 0.18
Extreme 0.181
0.2
1 month 0.18
Extreme 0.1802
0.21
Current year 0.15
Extreme 0.1502
0.25
1 year 0.15
Extreme 0.1502
0.97
3 years 0.15
Extreme 0.1502
4.73
5 years 0.15
Extreme 0.1502
141.5
10 years 0.15
Extreme 0.1502
298.5
Manager TitleAgeSince
Chief Executive Officer 53 2023-04-28
Chief Tech/Sci/R&D Officer 55 2024-04-28
Chief Tech/Sci/R&D Officer 54 2024-01-30
Director TitleAgeSince
Director/Board Member 72 2016-12-08
Chairman 69 2023-05-25
Director/Board Member 51 2020-12-31
Date Insider Type Main position Quantity % Market Cap.
11/15/22 Buy

Chief Executive Officer

150,000 0.6628%
5/24/22 Buy

Chief Executive Officer

100,000 0.4419%
5/21/22 Buy

Chief Executive Officer

100,000 0.4419%
Change 5-day change 1-year change 3-year change Capi.($)
-0.54%-6.98%-57.60%-85.30% 12.9M
-2.47%-1.90%+15.75%-25.65% 17.27B
+1.64%-5.48%+0.79%+91.39% 1.57B
-4.60%-7.32%-34.85%-80.45% 1.19B
+1.29%-4.72%-37.01%+15.19% 999M
-0.64%+2.18%-28.81%-52.65% 644M
-1.79%-5.76%-41.68%-57.20% 532M
+0.66%-1.67%+46.69%-54.40% 445M
0.00%+0.64%-54.33%-58.66% 382M
+1.09%+7.51%-18.78%-22.74% 364M
Average -0.54%-2.97%-20.98%-33.05% 2.34B
Weighted average by Cap. -1.92%-4.45%+6.26%-21.38%

Financials

2026 *2027 *
Net sales 3.2M 330K 290K 268K 246K 464K 31.85M 472K 1.25M 15.59M 1.24M 1.21M 53.7M 17.3M 1.79M 1.57M 1.45M 1.33M 2.51M 172M 2.55M 6.78M 84.26M 6.71M 6.56M 290M
Net income -91M -9.39M -8.23M -7.61M -7M -13.21M -906M -13.42M -35.67M -443M -35.27M -34.5M -1.53B -82M -8.46M -7.42M -6.86M -6.31M -11.9M -816M -12.09M -32.14M -399M -31.78M -31.09M -1.38B
Net Debt -67M -6.92M -6.06M -5.6M -5.15M -9.72M -667M -9.88M -26.26M -326M -25.97M -25.4M -1.12B -74M -7.64M -6.7M -6.19M -5.69M -10.74M -737M -10.91M -29.01M -360M -28.68M -28.06M -1.24B
Logo Immunovia AB
Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
Employees
17
Date Price Change Volume
26-07-20 SEK 0.1838 -0.54% 918,126
26-07-17 SEK 0.1848 -1.28% 1,087,469
26-07-16 SEK 0.1872 -3.21% 2,347,901
26-07-15 SEK 0.1934 -0.31% 1,296,442
26-07-14 SEK 0.1940 -1.52% 605,095

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMMNOV Stock